

## Freeform Search

|   |  |
|---|--|
| <b>Database:</b>  | US Pre-Grant Publication Full-Text Database<br>US Patents Full-Text Database<br>US OCR Full-Text Database<br>EPO Abstracts Database<br>JPO Abstracts Database<br>Derwent World Patents Index<br>IBM Technical Disclosure Bulletins |
| <b>Term:</b>  | L39 and l35 <div style="float: right; text-align: center;"> <input type="button" value="▲"/><br/> <input type="button" value="▼"/> </div>  |
| <b>Display:</b>   | <input type="text" value="10"/> Documents in <u>Display Format:</u> <input type="text" value="-"/> Starting with Number <input type="text" value="20"/>  |
| <b>Generate:</b> <input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image |  |

|        |       |           |
|--------|-------|-----------|
| Search | Clear | Interrupt |
|--------|-------|-----------|

### Search History

DATE: Thursday, November 03, 2005    [Printable Copy](#)    [Create Case](#)

| <u>Set</u><br><u>Name</u> <u>Query</u><br>side by<br>side   | <u>Hit</u><br><u>Count</u> | <u>Set</u><br><u>Name</u><br>result<br>set |
|---|----------------------------|--|
| <i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>  |                            |  |
| <u>L40</u> L39 and l35  | 11                         | <u>L40</u>                                 |
| <u>L39</u> non-aspirin or non aspirin or non-steroidal or non steroidal   | 16054                      | <u>L39</u>                                 |
| <u>L38</u> L37 and l35  | 8                          | <u>L38</u>                                 |
| <u>L37</u> rofecoxib or nabumetone or apazone or nimensulide or indomethacin or sulindac or etodolac  | 16683                      | <u>L37</u>                                 |
| <u>L36</u> l26 and l35  | 10                         | <u>L36</u>                                 |
| <u>L35</u> l5 or l29  | 242                        | <u>L35</u>                                 |
| <u>L34</u> l29 and l32  | 5                          | <u>L34</u>                                 |
| <u>L33</u> l29 same l32   | 0                          | <u>L33</u>                                 |
| <u>L32</u> naproxen or sodium daprofen or fenoprofen or ketoprofen or fluorbioprofen or oxaprozin or piroxicam or meloxicam or tenoxicam or ampiroxicam or droxicam or pivoxicam or phenylbutazone or oxyphenbutazone or antipyrine or aminopyrine or dipyrine or celecoxib | 15991                      | <u>L32</u>                                 |
| <u>L31</u> l8 same l29  | 5                          | <u>L31</u>                                 |
| <u>L30</u> L29 same l26   | 3                          | <u>L30</u>                                 |

|            |   |        |            |
|------------|---|--------|------------|
| <u>L29</u> | isoalpha acid or iso-alpha acid or iso alpha acid   | 240    | <u>L29</u> |
| <u>L28</u> | iso-alpha acid or isoalpha cid or iso alpha acid  | 209    | <u>L28</u> |
| <u>L27</u> | l26 same l6   | 0      | <u>L27</u> |
| <u>L26</u> | salicyclic acid or methyl salicylate or difulunisal or salsalate or olsalazine or sulfasalazine or acetanilide or acetanilide or acetaminophen or phenacetin or mefenamic acid or sodium meclofenamate or tolmetin or ketoorolac or diclofenac or ibuprofen | 43174  | <u>L26</u> |
| <u>L25</u> | l8 same l1  | 147    | <u>L25</u> |
| <u>L24</u> | l8 and l1   | 1509   | <u>L24</u> |
| <u>L23</u> | l8 and l1   | 1509   | <u>L23</u> |
| <u>L22</u> | L21 and l6  | 7      | <u>L22</u> |
| <u>L21</u> | ibuprofen   | 13883  | <u>L21</u> |
| <u>L20</u> | l19 and l8  | 6      | <u>L20</u> |
| <u>L19</u> | spent hops  | 141    | <u>L19</u> |
| <u>L18</u> | l10 same l1   | 6      | <u>L18</u> |
| <u>L17</u> | l10 and l1  | 123    | <u>L17</u> |
| <u>L16</u> | l8 and l15  | 23     | <u>L16</u> |
| <u>L15</u> | L14 same l13  | 1255   | <u>L15</u> |
| <u>L14</u> | boil\$6   | 683508 | <u>L14</u> |
| <u>L13</u> | hops  | 39768  | <u>L13</u> |
| <u>L12</u> | l6 and l10  | 1      | <u>L12</u> |
| <u>L11</u> | L10 and l8  | 6664   | <u>L11</u> |
| <u>L10</u> | naproxen  | 8316   | <u>L10</u> |
| <u>L9</u>  | l6 and l8   | 10     | <u>L9</u>  |
| <u>L8</u>  | anti-inflammatory or pain or antiinflammatory or anti inflmmatory   | 164239 | <u>L8</u>  |
| <u>L7</u>  | L6 same l2  | 2      | <u>L7</u>  |
| <u>L6</u>  | l4 or l5  | 69     | <u>L6</u>  |
| <u>L5</u>  | dihydro-isohumulone or dihydro-isocohumulone or dihydro-adhumulone  | 10     | <u>L5</u>  |
| <u>L4</u>  | isoalpha acid   | 65     | <u>L4</u>  |
| <u>L3</u>  | l1 same l2  | 48     | <u>L3</u>  |
| <u>L2</u>  | anti-inflammatory   | 63944  | <u>L2</u>  |
| <u>L1</u>  | beer  | 59387  | <u>L1</u>  |

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAU188MXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 5 AUG 30 CA/Caplus -Increased access to 19th century research documents  
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 8 OCT 03 MATHDI removed from STN  
NEWS 9 OCT 04 CA/Caplus-Canadian Intellectual Property Office (CIPO) added  
to core patent offices  
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America  
NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005  
NEWS 12 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download  
of Caplus documents for use in third-party analysis and  
visualization tools  
NEWS 13 OCT 27 Free KWIC format extended in full-text databases  
NEWS 14 OCT 27 DIOGENES content streamlined  
NEWS 15 OCT 27 EPFULL enhanced with additional content  
  
NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:05:56 ON 03 NOV 2005

=> file ca, biosis, medline

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

0.21

TOTAL

SESSION

0.21

FILE 'CA' ENTERED AT 15:06:14 ON 03 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:06:14 ON 03 NOV 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:06:14 ON 03 NOV 2005

=> s (iso-alpha acid?) or (isoalpha acid?)  
L1 432 (ISO-ALPHA ACID?) OR (ISOALPHA ACID?)

=> s anti-inflammatory or antiinflammatory or anti-inflmmatory or pain?  
L2 732900 ANTI-INFLAMMATORY OR ANTIINFLMMATORY OR ANTI-INFLMMATORY OR PAIN?

=> s l1 and l2  
L3 8 L1 AND L2

=> d 1-8 ab,bib

L3 ANSWER 1 OF 8 CA COPYRIGHT 2005 ACS on STN

AB The invention provides a composition comprising a reduced **isoalpha acid** (RIAA), selected from dihydroisohumulone, dihydroisocohumulone and dihydroadhumulone, and **isoalpha acid** (IAA), selected from isohumulone, isocohumulone, and isoadhumulone, isolated from hops, wherein the RIAA and IAA are in a ratio of about 3:1 to about 1:10. The invention also provides a method of reducing inflammation by administering a composition comprising a reduced **isoalpha acid** (RIAA) and **isoalpha acid** (IAA) isolated from hops, wherein the RIAA and IAA are in a ratio of about 3:1 to about 1:10. For example, synergy of PGE2 inhibition produced by four combinations of RIAA and IAA (3:1, 3:2, 1:1 and 1:10, resp.) was demonstrated in Raw 264.7 cells. Particularly relevant synergy occurred at the 1:1 and 1:10 RIAA/IAA ratios, at RIAA concns. <0.58 µg/mL and RIAA concns. >0.31 µg/mL.

AN 143:253900 CA

TI Synergistic **anti-inflammatory** compositions comprising an **isoalpha acid** and a reduced **isoalpha acid** from hops

IN Babish, John G.; Tripp, Matthew L.; Bland, Jeffrey S.

PA USA

SO U.S. Pat. Appl. Publ., 21 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

|      | PATENT NO.     | KIND   | DATE     | APPLICATION NO. | DATE     |
|------|----------------|--|----------|-----------------|----------|
| PI   | US 2005192356  | A1   | 20050901 | US 2004-789814  | 20040227 |
|      | WO 2005084680  | A1   | 20050915 | WO 2005-US6216  | 20050226 |
|      | W:             | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |          |
|      | RW:            | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |          |
| PRAI | US 2004-789814 | A  | 20040227 |                 |          |

L3 ANSWER 2 OF 8 CA COPYRIGHT 2005 ACS on STN

AB A key component of inflammation is the increase in prostaglandin biosynthesis resulting from induction of the cyclooxygenase 2 (COX2) gene. The COX2 enzyme is the prime target of non-steroidal **anti-inflammatory** drug (NSAID) therapy. COX2 is constitutively expressed in some tissues such as the gastrointestinal tract and its inhibition may result in GI toxicity. Our goal was to identify inhibitors

of prostaglandin production that were not direct COX enzyme inhibitors. We screened natural products for inhibition of prostaglandin E2 production in lipopolysaccharide (LPS)-induced mouse macrophage RAW 264.7 cells. Altering the test, methodol. allowed circumstantial assessment of in vitro inhibition of COX1 and COX2 enzymes, or COX2 gene induction. Various hop (hydrophobic and hydrophilic) and modified (IAA, RIAA, THIAA, HHIAA) hop exts. were found to be among the most potent PGE2 inhibitors in LPS induced (PGE2 from COX2) but not non-induced (PGE2 from COX1) RAW 264.7 cells, indicating COX2 selectivity (ranging from 1.5- to 363-fold). In a human gastric mucosal cell (AGS) model where COX2 is constitutively expressed, a CO2 hop extract showed strong inhibition of PGE2; in contrast, no significant PGE2 inhibition was observed by the other hop exts., indicating a lack of direct COX enzyme inhibition. Correlating the in vitro models [log10 (IC50AGS/IC50 RAW264.7)] allowed us to calculate a therapeutic index for each hop extract compared to various NSAIDs. We conclude that RIAA, IAA, THIAA, HHIAA, BA, and AA have strong potential as **anti-inflammatory** agents and predict, from our models, that they may have a low GI toxicity. An RIAA based **anti-inflammatory** preparation, Meta050, was tested clin. in a human pilot trial and showed efficacy against osteoarthritis **pain**.

AN 143:186388 CA  
 TI Hop and modified hop extracts have potent in vitro **anti-inflammatory** properties  
 AU Tripp, M.; Darland, G.; Lerman, R.; Lukaczer, D.; Bland, J.; Babish, J.  
 CS Metagenics Research and Development, Gig Harbor, WA, 98332, USA  
 SO Acta Horticulturae (2005), 668(Proceedings of the 1st International Humulus Symposium, 2004), 217-227  
 CODEN: AHORA2; ISSN: 0567-7572  
 PB International Society for Horticultural Science  
 DT Journal  
 LA English  
 RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CA COPYRIGHT 2005 ACS on STN  
 AB The invention provides hops ( Humulus lupulus ) exts. or derivs. thereof, such as humulone, cohumulone, adhumulone, isohumulone, etc., for use in treating a patient prophylactically and/or therapeutically for ulcerogenic-type disorders of the stomach and/or intestines. The ulcerogenic disorders can be induced chemical, environmentally, by infection, and/or by stress. The invention also provides a pharmaceutical composition comprising an active amount of hops exts. or derivs. thereof, in combination with an analgesic compound and/or an **anti-inflammatory** compound. The invention further provides for use of hops exts. or derivs. thereof, significantly reducing and/or therapeutically treating ulcerogenic-type disorders of the stomach and/or intestines. For example, the hop preparation Redihop containing rho-**iso-.alpha.-acids** when combined with NSAIDs (ibuprofen and aspirin) not only attenuated the gastropathy of NSAIDs by decreasing an inhibition of PGE2 synthesis in AGS human gastric mucosal cells, but also increased therapeutic indexes of both ibuprofen and aspirin.

AN 141:400871 CA  
 TI **Anti-inflammatory** pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity  
 IN Babish, John G.; Tripp, Matthew L.; Bland, Jeffrey S.; Howell, Terrence; Darland, Gary K.; Lerman, Robert H.; Lukaczer, Daniel O.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 689,856.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 6

|    | PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|----|---------------|------|----------|-----------------|----------|
| PI | US 2004219240 | A1   | 20041104 | US 2004-774048  | 20040205 |
|    | US 2003008021 | A1   | 20030109 | US 2001-885721  | 20010620 |
|    | US 2004086580 | A1   | 20040506 | US 2003-464410  | 20030618 |
|    | US 2004115290 | A1   | 20040617 | US 2003-464834  | 20030618 |

US 2004151792 A1 20040805 US 2003-689856 20031020  
WO 2005039483 A2 20050506 WO 2004-US16043 20040521  
WO 2005039483 A3 20050929

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

PRAI US 2001-885721 A2 20010620  
US 2002-420383P P 20021021  
US 2003-450237P P 20030225  
US 2003-400293 B2 20030326  
US 2003-401283 B2 20030326  
US 2003-472460P P 20030522  
US 2003-464410 A2 20030618  
US 2003-464834 A2 20030618  
US 2003-689856 A2 20031020  
US 2004-774048 A 20040205  
OS MARPAT 141:400871

L3 ANSWER 4 OF 8 CA COPYRIGHT 2005 ACS on STN

AB Compns. are provided including a synergistic combination of hops  
**isoalpha acids** and one or more isoflavones selected from  
genistein, genistin, daidzein, daidzin, glycitein and glycitin, wherein  
the weight ratio of hops **isoalpha acid** extract to  
isoflavones is from 1:50 to 50:1, calculated as aglycon. These compns. can be  
used as an **anti-inflammatory** agent or as a skin agent  
in particular for anti-ageing purposes. Examples given include Hops  
**isoalpha acids** increase procollagen and decorin  
synthesis in skin cells and the acids act synergistically to inhibit  
prostaglandin E2 expression in skin fibroblasts in response to stress.

AN 141:271563 CA

TI Hops **isoalpha acids** and isoflavones for **anti**  
**-inflammatory** and anti-ageing compositions

IN Yates, Paula Rachel

PA Unilever PLC, UK; Unilever NV; Hindustan Lever Limited

SO PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

|    | PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|----|---|------|----------|-----------------|----------|
| PI | WO 2004082697   | A1   | 20040930 | WO 2004-EP1785  | 20040224 |
|    | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,<br>LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,<br>NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,<br>TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW<br>RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,<br>BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,<br>ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,<br>TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG |      |          |                 |          |

PRAI GB 2003-6568 A 20030321

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CA COPYRIGHT 2005 ACS on STN

AB Disclosed is a novel **anti-inflammatory** pharmaceutical  
composition that exhibits potent and selective inhibition of the  
cyclooxygenase-2 (COX-2) enzyme. The formulation consists of a hops extract

that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concns. that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and fall in the range 0.011-0.2. Such compns. may also optionally contain high levels of  $\alpha$ -acids and low levels of  $\beta$ -acids, some flavonoid compds., and virtually no essential oils. Such compns. are useful for treating conditions that manifest as inflammatory **pain**, or are impacted by the COX-2 enzyme. The compns. are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic **pain** with reduced gastric side-effects. A hops extract contained  $\alpha$ -acids 88,  $\beta$ -acids 3.2, and **iso-.alpha. acids** 3%. The hops extract was more potent and selective than ibuprofen for inhibition of COX-2.

AN 141:111612 CA  
 TI Hop extracts as **anti-inflammatory** cyclooxygenase-2-selective inhibitors  
 IN Kuhrts, Eric H.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 8 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

|      | PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|------|--|------|----------|-----------------|----------|
| PI   | US 2004137096  | A1   | 20040715 | US 2003-340183  | 20030109 |
|      | WO 2004062611  | A2   | 20040729 | WO 2004-US613   | 20040109 |
|      | WO 2004062611  | A3   | 20050407 |                 |          |
| W:   | AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB,<br>BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR,<br>CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG,<br>ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU,<br>ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ,<br>KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN,<br>MW, MX, MX, MZ |      |          |                 |          |
| PRAI | US 2003-340183   | A    | 20030109 |                 |          |

L3 ANSWER 6 OF 8 CA COPYRIGHT 2005 ACS on STN  
 AB Disclosed is a pharmaceutical composition including a therapeutic quantity of a COX-2 inhibitor having an IC50-WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis or acute **pain** with less side-effects and faster onset of action utilizing the disclosed pharmaceutical composition A soft gelatin capsule was prepared by mixing a 70 % **iso-.alpha. acid** extract of hops with glycerin and other suitable excipients.

AN 138:374184 CA  
 TI Novel **anti-inflammatory** cyclooxygenase inhibitors having decreased gastrointestinal and cardiovascular toxicity  
 IN Kuhrts, Eric Hauser  
 PA USA  
 SO U.S. Pat. Appl. Publ., 10 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

|      | PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|------|---------------|------|----------|-----------------|----------|
| PI   | US 2003091656 | A1   | 20030515 | US 2001-8778    | 20011113 |
| PRAI | US 2001-8778  |      | 20011113 |                 |          |

L3 ANSWER 7 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
 AB Objective: Research suggests that osteoporosis is associated with systemic inflammation. We have previously shown that a reduced **iso-alpha acids** (RIAA), rosemary extract, and oleanolic acid supplement has **anti-inflammatory** effects by inhibiting COX-2-induced PGE2. We evaluated the anti-resorptive effects of this

supplement in osteoarthritis (OA) patients. Methods: An 8-week open-label pilot trial with the proprietary supplement in OA patients. Second morning urine was collected at initiation and conclusion. Bone resorption was measured using the collagen N-telopeptide (NTX) assay. Urinary NTX was converted to logarithm data to insure normal distribution and a 2-way ANOVA with interaction was performed. Tukey and Kramer's test for honestly significant difference was performed post hoc. Results: 37 OA patients started the trial and 32 completed: 9 males (average age 53.6), 23 females (average age 50.7). A statistically significant ( $p < 0.005$ ) decrease in NTX was observed from the initial elevation of  $66.9 \pm 7.96$  (se) nmol BCE/mM to  $38.2 \pm 3.39$  nmol BCE/mM after 8 weeks on the supplement. Conclusions: This observation suggests that the proprietary RIAA, rosemary extract, and oleanolic acid supplement with **anti-inflammatory** properties may be useful in improving bone mineral density. Further controlled trials are planned. Research was funded by Metagenics, Inc.

AN 2004:292219 BIOSIS

DN PREV200400291701

TI Assessment of bone resorption in osteoarthritic subjects using a proprietary reduced **iso-alpha acids**, rosemary extract, and oleanolic acid supplement.

AU Lerman, Robert H [Reprint Author]; Lukaczer, Dan O; Darland, Gary K; Liska, DeAnn J; Schiltz, Barbara C; Tripp, Matthew L; Bland, Jeffrey S  
CS Functional Medicine Research Center, Metagenics Inc., 9770 44th Ave NW, Gig Harbor, WA, 98332, USA  
boblberman@metagenics.com

SO FASEB Journal, (2004) Vol. 18, No. 4-5, pp. Abst. 608.3.

<http://www.fasebj.org/>. e-file.

Meeting Info.: FASEB Meeting on Experimental Biology: Translating the Genome. Washington, District of Columbia, USA. April 17-21, 2004. FASEB. ISSN: 0892-6638 (ISSN print).

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 23 Jun 2004

Last Updated on STN: 23 Jun 2004

L3 ANSWER 8 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AB Objective: We have shown that a supplement of reduced **iso-alpha acids** (RIAA), rosemary extract, and oleanolic acid inhibits COX-2-specific PGE2 production in vitro. We assessed this supplement for effects on Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Fibromyalgia (FM) in an open-label, 8 week trial. Methods: Supplement dose was 3 tabs/day for 4 weeks, which was continued or increased (4 tabs/day) for the subsequent 4 weeks, depending upon clinical response. **Pain** and quality-of-life were assessed using the Visual Analog Scale (VAS) and MOS Short-Form 36 (SF-36), respectively. Condition-specific data included the abridged Arthritis Impact Measurement Scale (AIMS2) for OA and RA, and the Fibromyalgia Impact Questionnaire (FIQ) for FM. Results: 62 subjects entered and 54 completed: 11 males (34-65 y), 43 females (28-68 y). Thirty-two subjects had OA, 19 FM, and 3 RA. OA subjects showed a 50% decrease in **pain** by VAS ( $p < 0.0001$ ; Wilcoxon-ranked sums) after supplementation. This decrease in **pain** was consistently observed in the AIMS2 and SF-36 **pain** subscale. No significant change in **pain** was seen for FM. Although **pain** decreased in RA, too few subjects precluded conclusions. Conclusions: The consistent findings of decreased **pain** specific for OA suggest that the RIAA, rosemary, and oleanolic acid supplement is the primary factor in **pain** improvement. Research supported by Metagenics, Inc. .

AN 2004:292123 BIOSIS

DN PREV200400291605

TI Benefits of a proprietary reduced **iso-alpha acids** (hops), rosemary extract, and oleanolic acid supplement on **pain** in subjects with osteoarthritis.

AU Lukaczer, Dan O [Reprint Author]; Lerman, Robert H; Darland, Gary K; Liska, DeAnn J; Schiltz, Barbara C; Tripp, Matthew L; Bland, Jeffrey S  
CS Functional Medicine Research Center, Metagenics Inc., 9770 44th Ave NW,

Gig Harbor, WA, 98332, USA

danlukaczer@metagenics.com

SO FASEB Journal, (2004) Vol. 18, No. 4-5, pp. Abst. 354.10.

, <http://www.fasebj.org/>. e-file.

Meeting Info.: FASEB Meeting on Experimental Biology: Translating the  
Genome. Washington, District of Columbia, USA. April 17-21, 2004. FASEB.  
ISSN: 0892-6638 (ISSN print).

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 23 Jun 2004

Last Updated on STN: 23 Jun 2004